ACD/Labs has announced the launch of a web-based application—Percepta Portal. The Portal offers ACD/Labs’ molecular property calculators and predictors in a modern technological environment.
ACD/Labs has announced the launch of a new web-based application in support of high throughput (HT) experimentation. Katalyst D2D offers a single interface for high throughput experimentation and parallel synthesis
ACD/Labs has announced significant updates across its ACD/Spectrus and Percepta platforms
Externalization of R&D activities and the deluge of instrumental analytical data generated on a daily basis has resulted in increasing interest in analytical data standardization. Any standardization efforts, however, to either a single format or for data exchange between formats; should be weighed against the requirements of different users of that data, and hardware innovations.
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
